REG - Yourgene Health PLC - Director/PDMR Shareholding

Yourgene HealthAnnouncement

24/09/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200924:nRSX9387Za

RNS Number : 9387Z  Yourgene Health PLC  24 September 2020

 

Yourgene Health plc

("Yourgene" or the "Company")

 

Director/PDMR Shareholding

 

Manchester, UK - 24 September 2020: Yourgene (AIM: YGEN), the international
molecular diagnostics group, announces that it was notified today of the
following directors' share purchases.

 

The following directors have made the following share purchases on 23
September 2020:

 

 Director       Purchase price  Number of shares purchased  Total number of shares owned following purchase  Percentage of issued share capital held following purchase
 Adam Reynolds  17 pence        294,117                     6,743,773                                        0.92%
 Lyn Rees       17 pence        294,000                     1,037,902                                        0.14%

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.

 

 Yourgene Health plc                                                           Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                                             investors@yourgene-health.com
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Cairn Financial Advisers LLP (NOMAD)                                          Tel: +44 (0)20 7213 0880
 Liam Murray / James Caithie / Ludovico Lazzaretti

 N+1 Singer (Joint Corporate Broker)                                           Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                       Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
  Paul McManus / Lianne Cawthorne                                              Mob: 07980 541 893 / Mob: 07584 391 303

 

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and
commercialises genetic products and services. The group works in partnership
with global leaders in DNA technology to advance diagnostic science.

 

Yourgene develops and commercialises simple and accurate molecular diagnostic
solutions, for reproductive health and molecular genetics. The Group's
products include non-invasive prenatal tests (NIPT) for Down's Syndrome and
other genetic disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's
commercial footprint is already established in the UK, Europe, the Middle
East, Africa and Asia.

 

Our product development, research service and commercial capabilities extend
across the lifecycle of genetic test development including regulatory
submissions. Through our technical expertise and partnerships, Yourgene is
also extending its genetic testing offering into oncology.

 

Yourgene is headquartered in Manchester, UK with offices in Taipei, Singapore,
the US and Canada and is listed on the London Stock Exchange's AIM market
under the ticker "YGEN". For more information, visit www.yourgene-health.com
(http://www.yourgene-health.com/)  and follow us on twitter @Yourgene_Health.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         a) Adam Reynolds

                                                                  b) Lyn Rees

 2   Reason for notification
 a.  Position/Status                                              a) Non-executive Chairman

                                                                  b) Chief Executive Officer
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Yourgene Health plc
 b.  LEI                                                          213800UUIT8BZE7QEH33
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of 0.1p each

Identification Code

                                                                  ISIN: GB00BN31ZD89
 b.  Nature of the transaction                                    Purchase
 c.  Price(s) and volume(s)
                                                                               Price(s)     Volume(s)
     a) 17p                                                                    a) 294,117

     b) 17p                                                                    b) 294,000

 e.  Date of the transaction                                      23 September 2020
 f.  Place of the transaction                                     London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHKXLFLBKLEBBE